Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates
Follow the latest updates of the outbreak聽on our聽timeline.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Regeneron 色界吧s has announced the identification of hundreds of fully human antibodies against Covid-19, caused by the novel coronavirus.
The virus-neutralising antibodies came from Regeneron鈥檚 genetically-modified VelocImmune mice, which have an immune system similar to humans.
Furthermore, the company isolated antibodies from recovered Covid-19 patients.
Regeneron plans to choose the top two antibodies to create a 鈥榗ocktail鈥� therapy given as prophylaxis or a treatment for infected people.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMeanwhile, the company is using its VelociMab technology to formulate manufacturing-ready cell lines to enable immediate clinical-scale production of selected antibodies.
The aim is to generate several thousands of prophylactic doses per month by later this year. Regeneron also intends to produce smaller quantities for initial clinical testing in June or August.
Furthermore, the company partnered with the US Health & Human Services’ Biomedical Advanced Research and Defense Authority (BARDA) to boost capacity.
Regeneron 色界吧s co-founder, president and chief scientific officer George Yancopoulos said: 鈥淥ur three decades of investment in our VelociSuite antibody technologies, which accelerate and improve the traditional drug discovery process, have hopefully prepared us for this critical time and to meet this important challenge.
鈥淕iven the tremendous interest and concern around the Covid-19 pandemic, we will be providing regular and transparent updates on our discovery and development programmes.鈥�
The company鈥檚 antibodies should act on the spike protein required by the virus to infect host cells.
Separately, Regeneron and Sanofi initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19.
